Navigation Links
Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
Date:9/12/2007

re consistent with the increased glucose control observed in diabetes animal models where a short treatment with E1-I.N.T.(TM) resulted in a sustained increase in beta cell mass and function. These clinical improvements, including HbA1c reductions greater than 1% in patients six month post-treatment, highlight the potential that E1-I.N.T.(TM) therapy could provide patients significant clinical benefit in excess of six months.

These clinical data support the potential of gastrin as a therapeutic in combination with other diabetes therapies. Transition holds the exclusive rights to a series of proprietary gastrin based combination therapies including GLP1-I.N.T.(TM) (a combination of gastrin analogue, G1, and a GLP-1 analogue) and combination therapies of gastrins and DPP-IV inhibitors. Transition will continue the development of these combination therapies into clinical trials with type 1 and type 2 diabetes patients.

GLP1- I.N.T.(TM)

Transition's second Islet Neogenesis Therapy product, GLP1-I.N.T.(TM) is a combination of one of the leading diabetes drug candidates, Glucagon-Like-Peptide-1 ("GLP-1"), with G1. The Company will perform additional safety and tolerability studies in humans in preparation for Phase II clinical development. The Company has entered into an agreement with the JDRF to support the clinical development of GLP1-I.N.T.(TM) over the next two years.

Sustaining Financial Strength

-----------------------------

During the year ended June 30, 2007, the Company strengthened its cash position by completing an offering for 2,986,867 common shares for net cash proceeds of $23,964,751. Subsequent to the end of the year, the Company further strengthened its cash position by completing another private placement, issuing 1,736,107 common shares resulting in net cash proceeds of $23,976,404. The Company's cash and cash equivalents and short-term investments were $34,368,142 at June 30, 2007. The Company currently believes th
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Mans Transition from Foragers to Agriculturalist Led to Increase in Birth Rates
2. Rocky Transition to the Medicare Drug Program
3. Customized Post Operation Care Offers Patients a Smooth Transition to Patients into the Community
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Permanent Weight Loss Requires Transition to Healthy Eating
6. VBI Provides Potential Targets to Diabetes Therapeutics
7. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
8. PM announces a new health care order for India
9. Ramdoss Announces Introduction of RCH-II
10. Britain Announces Third Transfusion Related Mad Cow Case
11. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Tenn. (PRWEB) , ... July 31, 2015 , ... The ... Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to Fight ... focused on cancer research between Methodist Healthcare, The West Clinic and The University of ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... There’s no ... possible, even when it comes time to cook the next meal, making July the ... July by practicing best grilling tips and recipes. , Make the next cookout different ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... Rally Insurance Group, Inc. has re-branded their social media profiles to better connect ... way for consumers to communicate, find information, share insights and opinions. The Rally ...
(Date:7/31/2015)... ... 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc Board ... Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already ... for the exam easy and painless. MDLinx offers thousands of board-exam style questions ...
(Date:7/31/2015)... , ... July 31, 2015 , ... According to the article published July ... the Pasadena courthouse was contained and extinguished by the city’s fire department before it caused ... building at the time of the fire, and it was a fire alarm system that ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... to Include New Research on HIV Screening, Pandemic ... WASHINGTON, Oct. 17 More than 13,000 ... 3-7 to address the,nation,s top public health challenges ... Meeting., The conference will feature leading experts, ...
... The Morris Animal Foundation is,dedicated to funding research ... launched a five-year, $30-million global campaign to cure,canine ... Insurance has pledged one,million dollars towards this goal ... help dogs suffering from cancer now, as well ...
... Will Have Their Dreams Come True ... Stronger!, LAS VEGAS, Oct. 17 The Emerald Dream Team, ... a National Search,for 12 women who have been diagnosed with breast ... be whisked away, with a,guest, to Las Vegas on Dec. 26th, ...
... October 17, 2007John Wiley & Sons, Inc, (NYSE:JWa) (NYSE:JWb), ... and Medicine are Wiley authors. , Congratulations ... Martin Evans, Dr. Albert Fert, Dr. Peter Grnberg, Leonid ... Oliver Smithies on this recognition of their great achievements. ...
... Parents of Kids with Infectious Diseases (PKIDs) today announced ... of,Pertussis" to sound the alarm about the dangers of ... children from this deadly disease. Commonly known as ... infection. Particularly dangerous for babies, pertussis,can strike at any ...
... Oct. 17 The Well Life Center in Mesa,Arizona, ... announces the continuation of its "10 Healing Secrets to ... The,Arizona Special Olympics. This session will teach you ... 10 universal laws. Discover tips on how to set,health ...
Cached Medicine News:Health News:Thousands of Public Health Experts to Address Leading Issues at APHA Annual Meeting, Nov. 3-7 2Health News:Morris Animal Foundation Featured on NASCAR Racecar to Raise Awareness of Pet Cancer 2Health News:Morris Animal Foundation Featured on NASCAR Racecar to Raise Awareness of Pet Cancer 3Health News:The Emerald Dream Ball 2Health News:9 Wiley authors win Nobel Prizes 2Health News:MultiVu Video Feed: Parents of Kids With Infectious Diseases Sounds Alarm About the Dangers of Pertussis With "Silence the Sounds of Pertussis" Campaign 2
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
(Date:7/30/2015)... N.J. , July 30, 2015  Growth of ... switches as they bring former prescription users to the ... Kline forecasts robust Rx-to-OTC switch activity over ... categories emerging along with many new brands entering the ... occur over the next five years (even those with ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... 94 Percent of Men Maintained Normal Testosterone Levels Throughout ... ... 92 Percent of Men Expressed Satisfaction with NEBIDO, LEXINGTON, Mass., ... data on NEBIDO(R),(testosterone undecanoate), an investigational, long-acting intramuscular,injection for the treatment of ...
... Del., May 20 A new 12-week,study(2) ... maintenance,combination asthma therapy, SYMBICORT(R) (budesonide/formoterol fumarate,dehydrate) Inhalation ... in children ages 6 to 15 years ... corticosteroid (ICS).(2) Of note, the study included,efficacy ...
Cached Medicine Technology:Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 2Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 3Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 4Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 2Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 3Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 4Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 5
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... line has the right product for any ... from intubated patients to patients with tracheotomies. ... anesthesia and critical care applications., ,The ... for patients and staff members. This entire ...
... has the right product for any patient ... intubated patients to patients with tracheotomies. These ... and critical care applications., ,The Unti-Mist ... patients and staff members. This entire product ...
... condenser humidifiers (HCH) capture the patient`s exhaled ... the inspired gas. Small and compact, they ... hygroscopic benefits. Depending on the tidal volume ... model., ,The adult HCH is ideal ...
Medicine Products: